Ascending single dose study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of SAM-315 administered orally to healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs SAM 315 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 25 Jul 2007 New trial record.